DSM Biologics wins Australian governments contract to build and operate a first major mammalian-based biopharma manufacturing facility
DSM Biologics, part of the Netherlands-headquartered Royal DSM NV, says it has signed preliminary agreements to enter a partnership with the Queensland State Government and the Commonwealth of Australia to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane.
The over 70,000 square foot facility will offer mammalian process development and current Good Manufacturing Practice (cGMP) clinical and commercial manufacturing services. DSM Biologics will employ its global expertise and portfolio of proprietary technologies to offer Australia and clients from all over the world, state-of-the-art, world-class contract manufacturing services.
News welcomed by Medicines Australia as a spur for clinical trials
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze